中国医药指南
中國醫藥指南
중국의약지남
CHINA MEDICINE GUIDE
2014年
2期
21-22
,共2页
胃食管反流病%埃索美拉唑%铝碳酸镁%莫沙比利%慢性咳嗽
胃食管反流病%埃索美拉唑%鋁碳痠鎂%莫沙比利%慢性咳嗽
위식관반류병%애색미랍서%려탄산미%막사비리%만성해수
Gastroesophageal relfux disease%Es omeprazole%Mosapride%Hydrotalcite%Chronic cough
目的：观察埃索美拉唑、莫沙必利和铝碳酸镁联合应用治疗胃食管反流性咳嗽的临床疗效。方法35例胃食管反流性咳嗽患者随机为A组（n=12），B组（n=12）和C组（n=11），分别采用埃索美拉唑（20毫克/次，2次/日）+铝碳酸镁（1000毫克/次，3次/日）+莫沙比利（5毫克/次，3次/日）、埃索美拉唑+莫沙比利及铝碳酸镁+莫沙比利治疗。8周后评价临床咳嗽症状变化，8周后评价内镜下有效率。结果治疗8周后，A、B和C组临床症状总有效率分别为91.6%、91.6%和72.7%，内镜下黏膜炎症恢复总有效率分别为100%、91.6%和90.9%，A组临床症状显效率与B和C组有显著性差异（P<0.05），总有效率与C组存在显著性差异；内镜下黏膜改变有效率与C组相比存在显著性差异（P<0.05）。结论埃索美拉唑、莫沙必利和铝碳酸镁联合规律治疗可以改善胃食管反流引起的慢性咳嗽症状。
目的：觀察埃索美拉唑、莫沙必利和鋁碳痠鎂聯閤應用治療胃食管反流性咳嗽的臨床療效。方法35例胃食管反流性咳嗽患者隨機為A組（n=12），B組（n=12）和C組（n=11），分彆採用埃索美拉唑（20毫剋/次，2次/日）+鋁碳痠鎂（1000毫剋/次，3次/日）+莫沙比利（5毫剋/次，3次/日）、埃索美拉唑+莫沙比利及鋁碳痠鎂+莫沙比利治療。8週後評價臨床咳嗽癥狀變化，8週後評價內鏡下有效率。結果治療8週後，A、B和C組臨床癥狀總有效率分彆為91.6%、91.6%和72.7%，內鏡下黏膜炎癥恢複總有效率分彆為100%、91.6%和90.9%，A組臨床癥狀顯效率與B和C組有顯著性差異（P<0.05），總有效率與C組存在顯著性差異；內鏡下黏膜改變有效率與C組相比存在顯著性差異（P<0.05）。結論埃索美拉唑、莫沙必利和鋁碳痠鎂聯閤規律治療可以改善胃食管反流引起的慢性咳嗽癥狀。
목적：관찰애색미랍서、막사필리화려탄산미연합응용치료위식관반류성해수적림상료효。방법35례위식관반류성해수환자수궤위A조（n=12），B조（n=12）화C조（n=11），분별채용애색미랍서（20호극/차，2차/일）+려탄산미（1000호극/차，3차/일）+막사비리（5호극/차，3차/일）、애색미랍서+막사비리급려탄산미+막사비리치료。8주후평개림상해수증상변화，8주후평개내경하유효솔。결과치료8주후，A、B화C조림상증상총유효솔분별위91.6%、91.6%화72.7%，내경하점막염증회복총유효솔분별위100%、91.6%화90.9%，A조림상증상현효솔여B화C조유현저성차이（P<0.05），총유효솔여C조존재현저성차이；내경하점막개변유효솔여C조상비존재현저성차이（P<0.05）。결론애색미랍서、막사필리화려탄산미연합규률치료가이개선위식관반류인기적만성해수증상。
Objective To evaluate the effect of esomeprazole combined with mosapride and hydrotalcite on gastroesophageal relfux cough. Methods A total of 35 gastroesophageal relfux cough patients were randomly divided into groups A (n=12), B (n=12) and C (n=11), treated with esomeprazole(20 mg, bid) plus hydrotalcite(1000 mg, tid) plus mosapride(5 mg, tid), esomepra zole plus mosapride, and hydrotacite plus mo sapride, respectively. The clinical symptoms of cough were observed and analyzed after 8 weeks of treatment. Endoscopy was performed to evalu?ate the effective rate in the three groups. Results After 8 weeks of treatment, the total improvement rates were 91.6%, 91.6%and 72.7%in group A, B and C, and the change of gastric mucosa effective rates detected by endoscopy were 100%, 91.6%and 90.9%, respectively. The clinical symptoms improvement rate (P<0.05) were markedly higher in group A than those in B and C group, and the effective rate had signiifcant difference compared with group C. The change of gastric mucosa effective rate (P<0.05) detected by endoscopy had signiifcant difference compared with group C. Conclusion Esomeprazole combined with mosapride and hydrotalcite may be highly effec tive in the treatment of gastroesophageal relfux cough.
